Back to search results

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Hospital, Taiyuan, Shanxi, China

    Contact: Study coordinator (Sujun Han, MD, PhD) · hsjyz2022@163.com · 086-0351-4881611
    Contact: Principal Investigator (Nianzeng Xing, MD, PhD)

  • Fudan University Shanghai Cancer Center, Shanghai, China

    Contact: Study coordinator (Ying Shen, MD, PhD) · yshen@shca.org.cn · 086-021-64175590
    Contact: Principal Investigator (Dingwei Ye, MD, PhD)
Study leads

  • Yan Wu, MD

    Study Director

    C Ray Therapeutics (Chengdu) Co., Ltd.

  • Dingwei Ye, MD, PhD

    Study Chair

    Fudan University Shanghai Cancer Center, Fudan University

  • Nianzeng Xing, MD, PhD

    Study Chair

    Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences

View source on ClinicalTrials.gov(opens in a new tab)